10.2 Benign Breast Diseases & Breast Carcinoma

Key Takeaways

  • Fibroadenoma ('breast mouse') is the most common benign breast tumor in young women (<30 years), characterized by a firm, smooth, highly mobile, painless mass.
  • Triple Assessment for any suspicious breast lump consists of: 1) Clinical examination, 2) Imaging (ultrasound for <35 years, bilateral diagnostic mammography for ≥35 years), and 3) Histopathology (core needle biopsy).
  • Invasive Ductal Carcinoma (NST) is the most common histological type of breast cancer (~75-80%); pleomorphic clustered microcalcifications on mammography are pathognomonic early signs.
  • Molecular subtypes (Luminal A, Luminal B, HER2-enriched, Triple Negative) guide prognosis and systemic therapy, with Triple Negative carcinomas having the highest rate of early visceral recurrence.
  • Surgical resection options include Breast Conservation Therapy (BCT: wide local excision + RT + sentinel node biopsy) and Modified Radical Mastectomy (MRM), with careful preservation of the long thoracic and thoracodorsal nerves.
Last updated: July 2026

Benign Breast Diseases & Breast Carcinoma

Breast pathology ranges from benign developmental aberrations (ANDI - Aberrations of Normal Development and Involution) to life-threatening invasive carcinomas. A solid understanding of clinical presentation, diagnostic algorithms, staging, and surgical techniques is vital for UPSC CMS aspirants.


1. Benign Breast Conditions

Fibroadenoma

  • Demographics: Most common benign breast tumor in young women aged 15-30 years.
  • Pathology: Benign biphasic tumor consisting of epithelial and stromal elements. Histologically exhibits pericanalicular or intracanalicular growth patterns.
  • Clinical Features: Painless, firm, smooth, rubbery, well-circumscribed mass. Highly mobile within breast tissue, earning the classical sobriquet "breast mouse".
  • Giant Fibroadenoma: Defined as fibroadenoma >5 cm in size or >500 grams in weight.
  • Management: Reassurance and observation for small (<2 cm) lesions in young women (<25 yrs). Surgical excision indicated if >3 cm, rapidly growing, painful, or patient >35 years.

Fibrocystic Disease (Mammary Dysplasia)

  • Etiology: Aberrant response of breast tissue to cyclical ovarian hormonal stimulation (estrogen excess / progesterone deficiency).
  • Clinical Features: Cyclical mastalgia (worse premenstrually) and painful bilateral, diffuse, lumpy breast nodularity.
  • Histology: Cysts, apocrine metaplasia, sclerosing adenosis, and ductal epithelial hyperplasia. Epithelial hyperplasia with atypia carries a 4-5x increased risk of breast cancer.

Phyllodes Tumor (Cystosarcoma Phyllodes)

  • Pathology: Biphasic tumor with hypercellular stromal proliferation showing characteristic leaf-like projections under microscopy. Classified as Benign (70%), Borderline (15%), or Malignant (15%).
  • Clinical Features: Fast-growing, large, bosselated breast mass in women aged 40-50 years. Overlying skin is shiny, stretched, with dilated superficial veins, but non-adherent to skin/chest wall.
  • Management: Wide local excision with a 1 cm clear margin. Axillary lymph node dissection is NOT required because phyllodes tumors spread via the hematogenous route (metastasis to lungs/bones) rather than lymphatics.

Intraductal Papilloma

  • Clinical Presentation: Most common cause of spontaneous bloody or serosanguinous single-duct nipple discharge.
  • Location: Typically subareolar in major lactiferous ducts.
  • Management: Microdochectomy (excision of single affected duct - Urban procedure) or Hadfield's operation (total duct excision).

Fat Necrosis

  • Etiology: Follows direct breast trauma, prior surgery, or radiotherapy.
  • Clinical Significance: Mimics breast carcinoma both clinically (hard, irregular, fixed mass with skin tethering) and radiologically. Biopsy is essential and reveals lipid-laden foam cells, multinucleated giant cells, and cholesterol clefts.

2. Triple Assessment & Mammography

Any patient presenting with a discrete breast lump must undergo the Triple Assessment to achieve 99.9% diagnostic accuracy:

  1. Clinical Examination: History, bilateral breast inspection, palpation, and regional lymph node evaluation.
  2. Diagnostic Imaging:
    • Ultrasound (USG): Modality of choice in women <35 years (dense fibroglandular parenchyma). Excellent for differentiating fluid-filled cysts from solid masses.
    • Mammography: Modality of choice in women ≥35 years. Standard views: Craniocaudal (CC) and Mediolateral Oblique (MLO). Malignant features include irregular spicated masses, architectural distortion, and pleomorphic microcalcifications clustered (>5 per cm³).
    • BI-RADS Classification: BIRADS 1 (Normal), BIRADS 2 (Benign), BIRADS 3 (Probably benign, <2% risk, follow-up in 6 mo), BIRADS 4 (Suspicious, biopsy recommended), BIRADS 5 (Highly suggestive of malignancy, >95% risk), BIRADS 6 (Known biopsy-proven malignancy).
  3. Histopathological Confirmation:
    • Core Needle Biopsy (CNB): Gold Standard. Uses a 14-gauge automated tru-cut needle. Provides tissue architecture to distinguish invasive from in situ carcinoma and permits ER, PR, HER2 receptor testing.
    • FNAC: Cytological assessment only; cannot distinguish invasive ductal carcinoma from DCIS.

3. Histological Types & Molecular Subtypes of Breast Carcinoma

  • Invasive Ductal Carcinoma - Not Otherwise Specified (IDC-NOS): Accounts for 75-80% of all breast cancers.
  • Invasive Lobular Carcinoma (ILC): Accounts for 10-15%. Characterized by loss of E-cadherin expression. Frequently bilateral and multicentric. Shows an 'Indian file' pattern of single cells invading stroma.

Molecular Subtypes Table

SubtypeHormone Receptors (ER/PR)HER2 ReceptorKi-67 Proliferation IndexPrognosis & Key Therapy
Luminal AER+ and/or PR+HER2 negativeLow (<20%)Best prognosis; highly responsive to endocrine therapy (Tamoxifen / Letrozole).
Luminal BER+ and/or PR+HER2 +/-High (≥20%)Intermediate prognosis; requires endocrine therapy + chemotherapy +/- Trastuzumab.
HER2-EnrichedER- and PR-HER2 positiveVariableAggressive; highly responsive to anti-HER2 targeted therapy (Trastuzumab / Pertuzumab).
Triple Negative (TNBC)ER-, PR-HER2 negativeHighWorst prognosis; frequent BRCA1 mutations; prone to early lung/brain metastases; chemotherapy main stay.

4. TNM Staging & Surgical Management

TNM Clinical Staging Highlights

  • T1: Tumor ≤ 2 cm in greatest dimension.
  • T2: Tumor > 2 cm but ≤ 5 cm.
  • T3: Tumor > 5 cm.
  • T4: T4a (chest wall fixation), T4b (skin involvement: ulceration, peau d'orange [dermal lymphatic embolization], skin nodules), T4c (both T4a and T4b), T4d (Inflammatory Breast Cancer - diffuse erythema, edema covering >1/3 of breast).
  • N1: Mobile ipsilateral Level I/II axillary lymph nodes.
  • N2: Fixed/matted ipsilateral axillary nodes.
  • N3: Ipsilateral infraclavicular (Level III), internal mammary, or supraclavicular nodes.

Surgical Operations

  1. Breast Conservation Therapy (BCT):
    • Components: Wide Local Excision (WLE with 1 cm clear margin) + Sentinel Lymph Node Biopsy (SLNB) / Axillary Lymph Node Dissection (ALND) + Whole Breast Postoperative Radiotherapy.
    • Absolute Contraindications: Multicentric disease (tumors in different quadrants), widespread malignant microcalcifications, prior chest wall radiation, persistent positive surgical margins after re-excision, pregnancy in 1st/2nd trimester.
  2. Modified Radical Mastectomy (MRM):
    • Auchincloss Procedure: Removes total breast tissue, nipple-areola complex, skin, pectoralis major fascia, and Level I & II axillary lymph nodes. Preserves pectoralis minor.
    • Patey Procedure: Includes division or excision of pectoralis minor to access Level III axillary nodes.

Axillary Dissection & Nerves at Risk

  • Level I Nodes: Lateral to lateral border of pectoralis minor.
  • Level II Nodes: Deep to pectoralis minor.
  • Level III Nodes: Medial to medial border of pectoralis minor.
  • Nerves to Preserve:
    1. Long Thoracic Nerve of Bell: Arises from C5, C6, C7; runs along lateral thoracic wall to supply Serratus Anterior. Injury leads to winged scapula (inability to push against a wall or abduct arm above 90°).
    2. Thoracodorsal Nerve: Supplies Latissimus Dorsi. Injury causes loss of extension, adduction, and internal rotation of the shoulder.
    3. Intercostobrachial Nerve: Sensory nerve crossing axilla; transection causes numbness over the upper medial arm.
Loading diagram...
Clinical Diagnostic & Surgical Workflow for Breast Mass
Test Your Knowledge

A 24-year-old female presents with a 2 cm, painless, smooth, rubbery, highly mobile lump in her right upper outer quadrant. What is the most likely diagnosis?

A
B
C
D
Test Your Knowledge

A 32-year-old lactating female presents with a discrete 3 cm firm left breast mass. Which initial imaging modality is most appropriate according to the Triple Assessment protocol?

A
B
C
D
Test Your Knowledge

A 55-year-old female presents with edema, thickening, and prominent skin pitting ('peau d'orange') over the lower quadrant of her left breast. What is the pathological mechanism responsible for this finding?

A
B
C
D
Test Your Knowledge

During a Patey modified radical mastectomy, a surgical resident inadvertently transects the Long Thoracic Nerve of Bell in the axilla. Which clinical deficit will the patient manifest postoperatively?

A
B
C
D